Abstract Lipoprotein (a)[Lp (a)] is a source of residual risk in patients with atherosclerotic
cardiovascular disease (ASCVD). Clinical trials of fully human monoclonal antibodies …

Stroke is the second leading cause of death and the third leading cause of disability
worldwide. Though the burden of stroke worldwide seems to have declined in the past three …

Background Use of lipoprotein (a) concentrations for identification of individuals at high risk
of cardiovascular diseases is hampered by the size polymorphism of apolipoprotein (a) …

Lipid-and lipoprotein-modifying therapies have expanded substantially in the last 25 years,
resulting in reduction in the incidence of major adverse cardiovascular events. However, no …

The role of lipoprotein-A [Lp (a)] as a risk factor for stroke is less well documented than for
coronary heart disease. Hence, we conducted a systematic review and meta-analysis for the …

Background and Purpose—Stroke and Alzheimer disease are 2 major causes of
neurological disability in aged people and shared overlapping predictors. In recent …

Background Elevated plasma lipoprotein (a)[Lp (a)] and coronary artery calcification (CAC)
are established cardiovascular risk factors that correlate with each other. We hypothesized …

Objective The metabolic mechanism of harmful effects of red meat on the cardiovascular
system is still unclear. The objective of the present study is to investigate the associations of …

In the United States, causes of racial differences in stroke and its risk factors remain only
partly understood, and there is a long-standing disparity in stroke incidence and mortality …

Background It is unclear whether lipoprotein (a) is associated with coronary heart disease
(CHD) and ischemic stroke events in White and Black adults with atherosclerotic …